Cover Image
Read Now

Triple conventional synthetic disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis a review of cost-effectiveness

The aim of this report is to summarize the cost-effectiveness evidence on triple csDMARDs therapy (specifically, methotrexate, sulfasalazine, hydroxychloroquine) relative to other pharmacologic options for the management of RA in North America

Bibliographic Details
Main Authors: Williams, D., Butcher, Robyn (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format: eBook
Language:English
Published: Ottawa CADTH March 26, 2019, 2019
Edition:Version: 1.0
Series:CADTH rapid response report
Subjects:
Antirheumatic Agents / Therapeutic Use
Arthritis, Rheumatoid / Drug Therapy
Cost-benefit Analysis
Meta-analysis As Topic
Treatment Outcome
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The aim of this report is to summarize the cost-effectiveness evidence on triple csDMARDs therapy (specifically, methotrexate, sulfasalazine, hydroxychloroquine) relative to other pharmacologic options for the management of RA in North America
Physical Description:1 PDF file (18 pages) illustration

Similar Items